ACTU

Actuate Therapeutics Inc (ACTU) Business Model Analysis (2026)

Invetso Score: 5.7/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Value Proposition Revenue Model

Score: 5.8 (Moderate)

Revenue mix: ACTU appears to rely on a standard operating revenue model, but the provided metrics do not disclose pricing power or recurring revenue structure.

Value capture: Zero reported R&D and capex ratios suggest a light asset model, yet the absence of segment detail limits evidence of differentiated monetization.

Peer context: Relative to scalable software or subscription peers, the model looks less structurally advantaged because revenue durability is not visible from the supplied data.

Cost Structure

Score:

Capital intensity: Capex-to-revenue and capex-to-OCF at zero indicate low reinvestment needs, which supports margin flexibility and cash conversion.

Operating structure: Low reported capital intensity can improve cost efficiency versus asset-heavy peers, but the data do not show fixed-cost leverage or labor intensity.

Structural constraint: The lack of disclosed operating cost detail prevents confirming whether the cost base scales cleanly with revenue.

Scalability Operating Leverage

Score:

Reinvestment burden: Minimal capex and R&D imply limited upfront scaling costs, which can support expansion without heavy incremental investment.

Operating leverage: Scalability remains unproven because the metrics do not show whether gross margins or operating margins expand with volume.

Peer context: Compared with software-like models, ACTU shows weaker evidence of compounding operating leverage, while still looking lighter than industrial peers.

Customer Structure Concentration

Score:

Customer visibility: No customer concentration or contract data are provided, so revenue dependence on a small set of buyers cannot be assessed.

Structural risk: The absence of disclosed recurring contracts or diversified end-market exposure lowers confidence in revenue resilience versus subscription peers.

Peer context: Relative to diversified B2B models, the customer structure is less transparent and therefore less predictable.

Revenue Quality Predictability

Score:

Cash conversion: Income quality of 0.97 suggests reported earnings are largely backed by cash, supporting revenue quality.

Predictability: FCF margin is unavailable, so the durability of cash generation and conversion consistency cannot be verified.

Peer context: Versus peers with recurring revenue disclosure, ACTU has weaker visibility even though the reported income quality is solid.

Overall Score

Score:

ACTU’s business model is supported by low capital intensity and solid income quality, but limited disclosure on revenue recurrence, customer concentration, and operating leverage constrains structural confidence.

Score Driver: Low Reinvestment Needs Are The Main Strength, While Weak Visibility Into Revenue Durability And Customer Structure Keeps The Model In The Moderate Range.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Actuate Therapeutics Inc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →